0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PLAU

PLAU

PLAU Molecule Information

Name:Urokinase plasminogen activator
Target Synonym:PLAU,uPA,Plasminogen Activator, Urokinase,Urokinase-Type Plasminogen Activator,Plasminogen Activator, Urinary,BDPLT5,U-PA,ATF,QPD,URK,EC:3.4.21.73,EC 3.4.21,U-Plasminogen Activator,EC 3.4.21.73
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

PLAU Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
PLU-H5228 Human Human PLAU / uPA Protein, His Tag (activated by trypsin) (active enzyme)
PLU-H5228-structure
PLU-H5228-sds
PLU-H5229 Human Human PLAU / uPA Protein, His Tag
PLU-H5229-structure
PLU-H5229-sds
PLU-H5229-elisa_1

PLAU Part of Bioactivity data

PLU-H5229-MALS-HPLC
Human PLAU, His TagHuman PLAU, His Tag (Cat. No. PLU-H5229) ELISA bioactivity

Immobilized Human PLAU, His Tag (Cat. No. PLU-H5229) at 5 μg/mL (100 μL/well) can bind Biotinylated Human uPAR, His,Avitag with a linear range of 0.3-2 ng/mL (QC tested).

PLAU Molecule Synonym Name

Urokinase,PLAU,ATF,UPA,URK,u-PA,BDPLT5,QPD

PLAU Molecule Background

Urokinase - type plasminogen activator is also known as PLAU and UPA, a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction).

PLAU References

PLAU Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Urokinase biosimilar (Bharat Serums & Vaccines) U-FRAG Approved Bharat Serums And Vaccines N; Pulmonary Embolism Details
Nasaruplase GE-0943 Approved Mitsubishi Pharma Corp Tomieze, Thrombolyse Japan Myocardial Infarction; Venous Thrombosis s:22:"Mitsubishi Pharma Corp"; 1992-01-01 Myocardial Infarction; Venous Thrombosis Details

PLAU Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Gallium-68 NOTA AE105 (Curasight) CS-001; 68Ga-NOTA-AE105 Phase 2 Clinical Curasight Head and Neck Neoplasms; Glioblastoma; Neuroendocrine Tumors; Mesothelioma; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Oropharyngeal Neoplasms; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung Details
Recombinant human annexin 5 protein (Yabao Pharmaceuticals) SY-005 Phase 1 Clinical Lawson Health Research Institute, Yabao Pharmaceutical Group Co Ltd Sepsis Details
Angstrom6 A6 Phase 2 Clinical Angstrom Ovarian Neoplasms; Peritoneal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell Details
tPA/HisproUK (Thrombolytic Science) TS-01 Phase 2 Clinical Thrombolytic Science Stroke Details
Upamostat Hydrogen Sulphate LH-011; WX-671 Phase 3 Clinical Wilex Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Breast Neoplasms; Colorectal Neoplasms Details

This web search service is supported by Google Inc.

totop